Schonfeld Strategic Advisors’s Aquestive Therapeutics AQST Stock Holding History

Schonfeld Strategic Advisors’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$215K	Buy	51,817 +33,013	+176%	+$134K	﹤0.01%	1708
2025 Q4	$121K	Sell	18,804 -10,139	-35%	-$63.2K	﹤0.01%	1791
2025 Q3	$162K	Buy	+28,943	New	+$125K	﹤0.01%	1977
2024 Q2	–	Sell	-62,747	Closed	-$267K	–	2131
2024 Q1	$267K	Buy	+62,747	New	+$209K	﹤0.01%	1696
2023 Q3	–	Sell	-16,900	Closed	-$27.9K	–	1757
2023 Q2	$27.9K	Buy	+16,900	New	+$30.6K	﹤0.01%	1867
2023 Q1	–	Sell	-506,600	Closed	-$457K	–	2080
2022 Q4	$457K	Buy	506,600 +99,900	+25%	+$93.8K	﹤0.01%	1577
2022 Q3	$475K	Buy	406,700 +325,600	+401%	+$368K	﹤0.01%	1790
2022 Q2	$52K	Sell	81,100 -18,900	-19%	-$25.1K	﹤0.01%	2216
2022 Q1	$261K	Sell	100,000 -5,700	-5%	-$16.6K	﹤0.01%	1770
2021 Q4	$411K	Buy	+105,700	New	+$530K	﹤0.01%	1365
2018 Q4	–	Sell	-11,192	Closed	-$196K	–	1048
2018 Q3	$196K	Buy	+11,192	New	+$184K	0.01%	761

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Schonfeld Strategic Advisors's AQST Position: Q1 2026 in Review

Schonfeld Strategic Advisors increased its Aquestive Therapeutics (AQST) stake by 176% in Q1 2026, buying an estimated $134K and bringing the position to 51,817 shares worth $215K. The position accounts for ﹤0.01% of the portfolio, ranked #1708.

Schonfeld Strategic Advisors first reported a position in AQST in Q3 2018 and has held it in 11 quarters since. The position peaked at $475K in Q3 2022. 179 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

Schonfeld Strategic Advisors held 51,817 shares of Aquestive Therapeutics worth $215K as of Q1 2026.
Schonfeld Strategic Advisors bought 33,013 Aquestive Therapeutics shares in Q1 2026, an estimated $134K.
Aquestive Therapeutics made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #1708 holding.
Schonfeld Strategic Advisors first reported a position in Aquestive Therapeutics in Q3 2018 and has held it in 11 quarters since.
Schonfeld Strategic Advisors's Aquestive Therapeutics position peaked at $475K in Q3 2022.
179 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.